Comments are closed.
Tweets by ambitioncm2020
AMBITION Electronic Data Capture Tool (EDC): Dr. David Lawrence’s YouTube Channel
AMBITION Protocol Version 2.2
The International Society for Neglected Tropical Diseases
International Society for Human and Animal Mycology
WHO: Meningitis
EDCTP and Horizon 2020
Horizon 2020 Annotated Model Grant Agreement
June 2020: Greene et al (Cryptococcal meningitis: a review of novel cryptococcal antigen screening programs in Africa. Expert Review of Anti-infective Therapy)
May 2020: Hurt et al (Prevalence and Sequelae of Cryptococcal Antigenemia in Antiretroviral Therapy-experienced Populations: An Evaluation of Reflex Cryptococcal Antigen Screening in Botswana. Clinical Infectious Diseases)
May 2020: Lebelonyane et al (Advanced HIV disease in the Botswana Combination Prevention Project: Prevalence, Risk Factors, and Outcomes)
May 2020: Wirth et al (Intervention coverage reaches UNAIDS 95-95-95 target for treatment and viral suppression in Botswana cluster-randomized trial)
May 2020: Nasuuna et al (Reduction in Baseline CD4 count testing following HIV “Treat All” adoption in Uganda clinics. Clinical Infectious Diseases)
May 2020: Lebelonyane et al (Rapid Antiretroviral therapy Initiation in the Botswana Combination Prevention Project)
May 2020: Jarvis et al (Evaluation of a Novel Semi-quantitative Cryptococcal Antigen Lateral Flow Assay in Patients with Advanced HIV Disease)
May 2020: Tenforde et al (Outcomes of reflex cryptococcal antigen (CrAg) screening in HIV-positive patients with CD4 counts of 100-200 cells/µL in Botswana)
April 2019: Ponatshego et al (High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study)
February 2019: Lawrence et al (Current Opinion in Infectious Diseases)
October 2018: Lawrence at al (Trials, 2018)
October 2018: Loyse et al: ‘Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries’
Gilead Sciences Announces Steep Discounts for Ambisome to Treat Cryptococcal Meningitis in Low- and Middle-Income Countries
August 2018: Adams & Nutt: A drug priced out of reach in Africa could save lives from a neglected killer
March 2018: Updated WHO Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children
London School of Hygiene & Tropical MedicineKeppel Street, London WC1E 7HT, UK
